ESR1 and breast carcinoma: Genomic testing has expanded and become more readily accessible to better guide benefit of adjuvant systemic treatment for patients with ER+ breast cancer.20–22 Thus, axillary staging may have less significance in deciding systemic treatment than genomic testing for many patients.23 In addition, there have been improvements of tailored systemic treatments with immunotherapy and precision oncology that have improved OS in select patients.